Air provided by high flow nasal therapy may more closely match the humidity and temperatures in the lower respiratory tract. Long-term high-flow nasal therapy reduces the subjective assessment of ...

Unlike the pivotal studies of ruxolitinib or fedratinib, phase 3 trials for pacritinib (PAC) enrolled patients with INT-1 risk. During the studies, a spleen volume reduction of at least 35% (SVR35) ...

Recently, I wrote about my regular sense of the need for another infusion for alpha-1 antitrypsin deficiency (AATD). After about 5 days following an infusion day, I tend to start feeling more out of ...

The core care team for TK2d may include a neuromuscular neurologist, pulmonologist, nutritionist, physical therapist, and orthopedist. A support care team may include specialists such as a ...

At current rates, Bangladesh is the sole South Asian country expected to meet the SDG neonatal mortality target by 2030. Accelerated efforts are needed if South Asian countries are to meet the ...

Patients with a history of transfusion were more likely to develop multiple alloantibodies than those with pregnancy as the only identified source for RhD alloimmunization. A recent retrospective ...

Testosterone levels positively correlated with hepatic fibrosis in patients with Wilson disease and PCOS. Polycystic ovary syndrome (PCOS) can be a frequent comorbidity in women with Wilson disease ...

Based on their findings, the researchers developed a new scoring system, IPSS-R-I, which demonstrated superior performance compared to the original IPSS-R system. Immunohistochemical profiling of bone ...

There was an increased risk of atrial fibrillation in the patients regardless of the presence of heart failure or other common atrial fibrillation causes. Individuals with alpha-1 antitrypsin ...

In total, 139 independent pharmacist or registered nurse visits took place, allowing clinicians to focus on other patient needs. Pharmacist and registered nurse (RN)-led management of venetoclax ...

The annualized relapse rate was 0.069 after the start of treatment with satralizumab and 0.445 within 52 weeks before the start of treatment with the drug. Treatment with satralizumab is associated ...

Neutropenia was a dose-limiting toxicity in patients who were Duffy positive and Duffy null, but the effect was more prominent in the Duffy-null group. Individuals with the Duffy null phenotype ...